Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3028 Target Snapshot

Prolyl hydroxylase EGLN2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
617Compounds
21Assays
0Approved Drugs
661.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Prolyl hydroxylase EGLN2 shows approved-linked disease relevance led by anemia (phenotype). 3 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q96KS0. Start with anemia (phenotype), then reuse UniProt Q96KS0 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with anemia (phenotype), then reuse UniProt Q96KS0 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
anemia (phenotype)

Prolyl hydroxylase EGLN2 shows approved-linked disease relevance led by anemia (phenotype). 3 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with anemia (phenotype) because it currently carries approved-linked support. Linked drugs include MOLIDUSTAT, VADADUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prolyl hydroxylase EGLN2 as ChEMBL target CHEMBL3028, mapped to UniProt Q96KS0. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prolyl hydroxylase EGLN2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3028
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96KS0
Prolyl hydroxylase EGLN2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Prolyl hydroxylase EGLN2 is the right protein anchor across sources, using UniProt Q96KS0 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why anemia (phenotype) is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameProlyl hydroxylase EGLN2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ96KS0
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProlyl hydroxylase EGLN2
UniProt AccessionQ96KS0
Component TypeProtein
Sequence Length407 aa

Prolyl hydroxylase EGLN2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Prolyl hydroxylase EGLN2, mapped to UniProt Q96KS0. Sequence length is 407 aa.

Mapped IDQ96KS0
Review nameProlyl hydroxylase EGLN2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Prolyl hydroxylase EGLN2 shows approved-linked disease relevance led by anemia (phenotype). 3 more disease programs remain visible in the same review block.

Approved-linked Approved
anemia (phenotype)
2 linked drugs · 2 direct · 2 efficacy
Linked drugMOLIDUSTAT
Linked drugVADADUSTAT
Approved-linked Approved
anemia
1 linked drug · 1 direct · 1 efficacy
Linked drugVADADUSTAT
Approved-linked Approved
chronic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugVADADUSTAT
Clinical signal Phase I
liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugVADADUSTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with anemia (phenotype) because it currently carries approved-linked support. Linked drugs include MOLIDUSTAT, VADADUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseanemia (phenotype)
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50659.0
KI2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2041169 9.7 IC50 0.2 Preclinical
CHEMBL2041175 9.7 IC50 0.2 Preclinical
CHEMBL2041182 9.7 IC50 0.2 Preclinical
CHEMBL2041185 9.7 IC50 0.2 Preclinical
CHEMBL2041190 9.7 IC50 0.2 Preclinical
CHEMBL2041193 9.7 IC50 0.2 Preclinical
CHEMBL2043169 9.7 IC50 0.2 Preclinical
CHEMBL2043325 9.7 IC50 0.2 Preclinical
CHEMBL2041010 9.52 IC50 0.3 Preclinical
CHEMBL2041178 9.52 IC50 0.3 Preclinical
Distribution

pChEMBL Value Distribution

65
5.0
109
5.5
104
6.0
104
6.5
70
7.0
27
7.5
33
8.0
27
8.5
13
9.0
18
9.5
pChEMBL
Assay Landscape

Assay Landscape

21
Total Assays
614
Tested Compounds
1
Assay Types
Binding — 21 assays, 614 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 11 272 6.1
single protein format 9 342 7.0
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine